first
phase
week
transplant
second
phase
month
transplant
third
phase
month
transplant
understand
factor
patient
allow
develop
differenti
diagnos
infecti
syndrom
transplant
recipi
prevent
strategi
prophylaxi
vaccin
appropri
individu
risk
infect
exposur
import
divid
four
overlap
categoriesdonorderiv
infect
recipientderiv
infect
communityderiv
exposur
nosocomi
exposur
tabl
infect
deriv
donor
tissu
activ
recipi
among
least
appreci
import
exposur
transplant
infect
latent
wherea
other
result
occurr
activ
infect
donor
time
procur
known
type
infect
recogn
transplant
recipi
three
type
infect
merit
special
attent
first
bacterem
fungem
infect
staphylococci
streptococcu
pneumonia
candida
salmonella
escherichia
coli
donor
time
donat
select
adher
anastomot
site
vascular
urinari
may
produc
leak
mycot
aneurysm
second
viral
infect
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
associ
particular
syndrom
morbid
immunocompromis
popul
see
section
select
infect
import
greatest
risk
infect
seroneg
immunolog
naiv
recipi
receiv
infect
graft
seroposit
donor
latent
viral
infect
third
late
latent
infect
tuberculosi
may
activ
mani
year
initi
exposur
infect
may
difficult
treat
establish
interact
antimicrobi
agent
use
treat
eg
rifampin
streptomycin
isoniazid
mycobacteria
agent
use
immunosuppress
therapi
donor
screen
transplant
limit
avail
technolog
time
avail
within
organ
deceas
donor
must
use
present
routin
evalu
donor
reli
antibodi
detect
serolog
test
common
infect
result
activ
infect
remain
undetect
seroconvers
may
occur
acut
infect
limit
suggest
achiev
benefit
transplant
organ
implant
carri
unidentifi
pathogen
risk
exhibit
cluster
donorderiv
trypanosoma
cruzi
chaga
diseas
rabi
viru
west
nile
viru
lymphocyt
choriomening
viru
infect
organ
transplant
recipi
success
manag
infect
renal
transplant
recipi
complic
factor
relat
immun
function
host
epidemiolog
infect
immunocompromis
host
transplant
recipi
suscept
broad
spectrum
infecti
pathogen
manifest
diminish
sign
symptom
invas
infect
may
develop
system
sign
eg
fever
respons
noninfecti
process
eg
graft
reject
drug
toxic
multipl
process
often
present
immunocompromis
patient
toler
invas
establish
infect
poorli
high
morbid
mortal
lend
urgenc
need
earli
specif
diagnosi
guid
antimicrobi
therapi
given
lymphocyt
dysfunct
inher
transplant
immunosuppress
viral
infect
particular
increas
viral
infect
contribut
graft
dysfunct
graft
reject
system
ill
also
enhanc
risk
opportunist
infect
eg
pneumocysti
aspergillu
viral
mediat
cancer
risk
infect
renal
transplant
recipi
determin
interact
two
key
factor
epidemiolog
exposur
patient
includ
time
intens
virul
organ
patient
net
state
immunosuppress
reflect
measur
host
factor
contribut
risk
infect
given
risk
transmiss
infect
organ
donor
recipi
certain
infect
consid
rel
contraind
organ
donat
renal
transplant
typic
elect
surgeri
reason
avoid
donat
individu
unexplain
fever
rash
infecti
syndrom
common
criteria
exclus
organ
donor
list
tabl
infect
categori
recipientderiv
exposur
reflect
colon
latent
infect
reactiv
set
immunosuppress
necessari
obtain
care
histori
travel
exposur
guid
prevent
strategi
empir
therapi
notabl
among
infect
mycobacteri
infect
includ
tuberculosi
strongyloidiasi
viral
infect
herp
simplex
viru
hsv
varicellazost
viru
vzv
shingl
histoplasmosi
coccidioidomycosi
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
vaccin
statu
evalu
tetanu
hbv
childhood
vaccin
influenza
pneumococcu
vaccin
previous
given
consid
tabl
dietari
habit
also
consid
includ
use
well
water
cryptosporidium
uncook
meat
salmonella
listeria
unpasteur
dairi
product
listeria
common
exposur
commun
often
relat
contamin
food
water
ingest
exposur
infect
famili
member
cowork
exposur
relat
hobbi
travel
work
infect
caus
common
respiratori
virus
influenza
respiratori
syncyti
viru
adenoviru
atyp
pathogen
hsv
vzv
carri
risk
viral
pneumonia
increas
risk
bacteri
fungal
superinfect
commun
contact
transfus
associ
exposur
cmv
ebv
may
produc
sever
primari
infect
nonimmun
host
recent
remot
exposur
endem
geograph
restrict
system
mycos
blastomyc
dermatitidi
coccidioid
immiti
histoplasma
capsulatum
mycobacterium
tuberculosi
result
local
pulmonari
system
metastat
infect
asymptomat
strongyloid
stercorali
infect
may
activ
year
initi
exposur
owe
effect
immunosuppress
therapi
fig
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfest
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
bacteremia
mening
gastroenter
secondari
salmonella
campylobact
jejuni
varieti
enter
virus
result
persist
infect
sever
prolong
diarrheal
diseas
increas
risk
primari
secondari
bloodstream
invas
metastat
infect
nosocomi
infect
increas
import
organ
signific
antimicrobi
resist
present
medic
center
includ
vancomycinresist
linezolidresist
quinupristindalfopristinresist
enterococci
methicillinresist
staphylococci
fluconazoleresist
candida
singl
case
nosocomi
aspergillu
infect
compromis
host
view
failur
infect
control
practic
antimicrobi
misus
inadequ
infect
control
practic
caus
increas
rate
clostridium
difficil
coliti
outbreak
infect
secondari
legionella
associ
hospit
plumb
contamin
water
suppli
ventil
system
nosocomi
infect
investig
ascertain
sourc
prevent
subsequ
infect
nosocomi
spread
pneumocysti
carinii
jiroveci
immunocompromis
patient
suggest
varieti
case
seri
respiratori
viral
infect
may
acquir
medic
staff
consid
among
caus
fever
respiratori
decompens
hospit
institution
immunocompromis
individu
net
state
immunosuppress
qualit
measur
risk
factor
infect
individu
includ
immunosuppress
medic
iatrogen
condit
standard
immunosuppress
regimen
specif
infect
occur
often
vari
predict
pattern
depend
time
elaps
sinc
transplant
fig
primarili
reflect
chang
risk
factor
time
surgeryhospit
immunosuppress
acut
chronic
reject
emerg
latent
infect
exposur
novel
commun
infect
pattern
infect
chang
alter
immunosuppress
regimen
pulsedos
steroid
intensif
graft
reject
intercurr
viral
infect
neutropenia
drug
toxic
graft
dysfunct
signific
epidemiolog
exposur
travel
food
timelin
remain
use
start
point
although
alter
introduct
new
immunosuppress
agent
pattern
use
includ
reduc
use
corticosteroid
calcineurin
inhibitor
increas
use
antibodybas
induct
therapi
sirolimu
routin
antimicrobi
prophylaxi
improv
molecular
assay
antimicrobi
resist
transplant
hivinfect
hcvinfect
individu
broader
epidemiolog
exposur
eg
travel
figur
show
three
overlap
period
risk
infect
transplant
associ
differ
pattern
common
pathogen
follow
periop
period
approxim
week
transplant
reflect
surgic
technic
complic
period
month
transplant
depend
rapid
taper
immunosuppress
use
antilymphocyt
induct
therapi
reflect
intens
immunosuppress
viral
activ
opportunist
infect
period
beyond
first
year
transplant
reflect
communityacquir
exposur
unusu
pathogen
base
level
mainten
immunosuppress
timelin
use
varieti
way
establish
differenti
diagnosi
transplant
patient
suspect
infect
provid
clue
presenc
excess
environment
hazard
individu
either
within
hospit
commun
serv
guid
design
prevent
antimicrobi
strategi
infect
occur
outsid
usual
period
unusu
sever
suggest
either
excess
epidemiolog
hazard
excess
immunosuppress
prevent
infect
must
link
risk
infect
variou
time
transplant
tabl
outlin
routin
prevent
strategi
massachusett
gener
hospit
strategi
serv
delay
onset
infect
face
epidemiolog
pressur
use
antibiot
prophylaxi
vaccin
behavior
modif
eg
routin
hand
wash
advic
dig
garden
without
mask
may
result
shift
right
infect
timelin
unless
intens
immunosuppress
reduc
immun
develop
first
month
transplant
three
type
infect
occur
first
type
infect
present
recipi
transplant
inadequ
treatment
emerg
set
surgeri
anesthesia
immunosuppress
pretransplant
infect
colon
recipi
resist
organ
infect
intraven
cathet
surgic
drain
also
common
eg
methicillinresist
staphylococcu
aureu
infect
control
erad
transplant
second
type
earli
infect
donor
deriv
type
may
nosocomi
deriv
resist
gramneg
bacilli
aureu
candida
secondari
system
infect
donor
eg
line
infect
contamin
organ
procur
process
end
result
high
risk
infect
vascular
sutur
line
mycot
aneurysm
rare
infect
transmit
donor
recipi
may
emerg
earlier
predict
eg
tuberculosi
histoplasmosi
third
common
sourc
infect
earli
period
relat
complex
surgic
procedur
transplant
infect
includ
surgic
wound
infect
pneumonia
aspir
bacteremia
secondari
vascular
access
surgic
drainag
cathet
urinari
tract
infect
infect
fluid
collectionsleak
vascular
urinari
anastomos
lymphocel
nosocomi
infect
due
antimicrobialresist
bacteria
candida
infect
observ
nonimmunosuppress
patient
undergo
compar
surgeri
given
immunosuppress
sign
infect
may
subtl
howev
sever
durat
usual
greater
technic
skill
surgeon
meticul
postop
care
ie
wound
care
proper
mainten
time
remov
endotrach
tube
vascular
access
devic
drainag
cathet
determin
risk
infect
anoth
common
infect
c
difficil
coliti
limit
periop
antibiot
prophylaxi
ie
singl
dose
hour
antibiot
cefazolin
usual
adequ
addit
coverag
known
risk
factor
eg
prior
colon
methicillinresist
aureu
pancrea
transplant
periop
prophylaxi
yeast
common
use
fluconazol
mind
potenti
increas
sirolimu
calcineurin
inhibitor
level
use
azol
antifung
agent
opportunist
infect
notabl
absenc
first
month
transplant
even
though
daili
dose
immunosuppress
drug
highest
time
implic
observ
import
suggest
daili
dose
immunosuppress
drug
import
rather
cumul
dose
drugsth
area
curv
determin
true
state
immunosuppress
net
state
immunosuppress
great
enough
support
occurr
opportunist
infect
unless
exposur
excess
occurr
singl
case
opportunist
infect
period
trigger
epidemiolog
investig
environment
hazard
infect
transplant
recipi
month
transplant
one
three
caus
infect
perisurg
period
includ
relaps
c
difficil
coliti
inadequ
treat
pneumonia
infect
relat
technic
problem
eg
urin
leak
lymphocel
hematoma
fluid
collect
set
gener
requir
drainag
period
stage
also
set
emerg
subgroup
patientsth
chronic
neer
well
patient
requir
higher
averag
immunosuppress
maintain
graft
function
prolong
untreat
viral
infect
opportunist
infect
predict
longterm
suscept
mani
infect
third
phase
discuss
later
patient
may
requir
prolong
lifelong
prophylaxi
antibacteri
antifung
antivir
combin
prevent
lifethreaten
infect
specif
opportunist
infect
occur
reflect
specif
immunosuppress
regimen
use
presenc
absenc
immunomodul
viral
infect
viral
pathogen
reject
respons
febril
episod
occur
period
period
anticmv
strategi
trimethoprimsulfamethoxazol
prophylaxi
effect
decreas
risk
infect
trimethoprimsulfamethoxazol
prophylaxi
effect
prevent
p
carinii
jiroveci
pneumonia
reduc
incid
urinari
tract
infect
urosepsi
l
monocytogen
mening
nocardia
infect
gondii
recipi
underw
tranplant
month
previous
divid
three
group
one
singlestrength
tmpsmx
tablet
contain
mg
trimethoprim
mg
sulfamethoxazol
oral
daili
minimum
mo
posttransplant
patient
infect
cmv
chronic
reject
recurr
infect
maintain
lifelong
prophylaxi
thriceweekli
regimen
tmpsmx
prevent
p
jiroveci
pneumonia
prevent
infect
eg
urinari
tract
infect
nocardia
listeria
toxoplasma
gastrointestin
pulmonari
infect
patient
proven
toler
tmpsmx
altern
regimen
includ
combin
atovaquon
mg
oral
daili
meal
plu
levofloxacin
mg
oral
daili
equival
fluoroquinolon
without
anaerob
activ
pentamidin
mg
intraven
inhal
everi
wk
dapson
mg
oral
daili
twice
weekli
without
pyrimethamin
agent
toxic
must
consid
eg
hemolysi
host
dapson
none
altern
program
offer
broad
protect
tmpsmx
cmv
prophylaxi
cmv
serolog
statu
without
alt
therapi
screen
antigenemia
r
ganciclovir
mgkg
intraven
load
dose
per
monthli
mo
renal
function
discharg
valganciclovir
gener
discontinu
mgday
renal
transplant
mo
therapi
r
alt
ganciclovir
mgkg
intraven
first
dose
per
renal
monthli
mo
function
discharg
valganciclovir
daili
mo
discontinu
therapi
r
alt
valganciclovir
mgday
renal
transplant
mo
symptom
r
famciclovir
mg
oral
daili
mo
valacyclovir
symptom
twice
day
acyclovir
three
time
day
feverneutropenia
use
cmvneg
leukocytereduc
blood
statu
unknown
al
ganciclovir
mgkg
intraven
first
dose
daili
correct
renal
function
serolog
statu
determin
term
infect
risk
transplant
recipi
technic
good
procedur
satisfactori
allograft
function
reduc
immunosuppress
absenc
chronic
viral
infect
patient
resembl
gener
commun
term
infect
risk
communityacquir
respiratori
virus
constitut
major
risk
occasion
patient
develop
primari
cmv
infect
social
acquir
infect
relat
underli
diseas
eg
skin
infect
diabet
second
group
patient
chronic
viral
infect
absenc
effect
antivir
therapi
often
reduct
immunosuppress
produc
endorgan
damag
eg
bk
polyomaviru
lead
nephropathi
hcv
lead
cryoglobulinemia
cirrhosi
cmv
chronic
graft
reject
malign
eg
posttransplant
lymphoprolif
diseas
ptld
secondari
ebv
skin
anogenit
cancer
secondari
papillomavirus
third
group
patient
unsatisfactori
allograft
function
requir
intens
immunosuppress
therapi
preserv
graft
function
result
patient
appear
overimmunosuppress
patient
may
chronic
viral
infect
repres
chronic
neerdowel
greatest
risk
opportunist
infect
give
patient
lifetim
mainten
trimethoprim
sulfamethoxazol
prophylaxi
often
fluconazol
prophylaxi
group
one
also
consid
organ
often
associ
immun
dysfunct
acquir
immunodefici
syndrom
aid
bartonella
rhodococcu
cryptosporidium
microsporida
invas
fungal
pathogen
aspergillu
zygomycet
dematiacea
pigment
mold
even
minim
sign
symptom
warrant
care
evalu
group
highrisk
patient
guidelin
pretranspl
screen
subject
sever
recent
public
includ
consensu
confer
immunocompromis
host
societi
american
societi
transplant
clinic
practic
guidelin
evalu
renal
transplant
candid
american
societi
transplant
surgeon
ast
clinic
practic
guidelin
evalu
live
renal
transplant
donor
transplant
donor
crucial
featur
screen
deceas
donor
time
limit
use
organ
must
procur
implant
microbiolog
assess
complet
major
infect
must
exclud
appropri
cultur
sampl
must
obtain
futur
refer
result
bacteremia
fungemia
may
detect
transplant
perform
infect
gener
result
transmiss
infect
long
infect
adequ
treat
term
use
antimicrobi
agent
organ
suscept
time
recipi
tissu
bacterem
donor
mean
day
effect
therapi
transplant
seem
adequ
prevent
transmiss
suscept
pathogen
longer
cours
therapi
recipi
prefer
target
known
donorderiv
pathogen
bacteri
mening
must
treat
antibiot
penetr
cerebrospin
fluid
organ
procur
certain
acut
infect
cmv
hsv
ebv
hiv
hcv
may
undetect
period
antibodi
format
viral
dna
detect
prefer
likewis
donor
clinic
social
medic
histori
essenti
reduc
risk
infect
presenc
known
infect
infect
must
treat
procur
possibl
sever
recent
cluster
donorderiv
infect
shown
risk
infect
secondari
previous
unrecogn
pathogen
includ
lymphocyt
choriomening
viru
chaga
diseas
hsv
addit
common
pathogen
major
exclus
criteria
outlin
tabl
contrast
abovedescrib
scenario
live
donor
procedur
consid
elect
evalu
complet
infect
treat
procedur
interim
histori
must
taken
time
surgeri
assess
presenc
new
infect
sinc
initi
donor
evalu
intercurr
infect
flulik
ill
headach
confus
myalgia
cough
might
harbing
import
infect
west
nile
viru
sever
acut
respiratori
syndrom
sar
cruzi
live
donor
undergo
batteri
serolog
test
tabl
purifi
protein
deriv
ppd
skin
test
indic
chest
radiograph
test
must
individu
base
uniqu
risk
factor
eg
travel
particular
import
renal
transplant
recipi
exclus
urinari
tract
infect
includ
yeast
bacteremia
time
donat
mycobacterium
tuberculosi
donor
repres
approxim
report
posttranspl
tuberculosi
case
review
patient
singh
paterson
activ
diseas
exclud
ppdposit
donor
chest
radiograph
sputum
cultur
chest
comput
tomographi
ct
chest
radiograph
abnorm
urin
acidfast
bacillu
cultur
may
use
ppdposit
kidney
donor
isoniazid
prophylaxi
recipi
consid
untreat
ppdposit
donor
factor
favor
prophylaxi
includ
donor
endem
region
use
highdos
steroid
regimen
highrisk
social
environ
chaga
diseas
cruzi
transmit
transplant
endem
area
recent
unit
state
schistosomiasi
infect
stercorali
gener
recipientderiv
problem
ebv
infect
major
risk
factor
develop
ptld
risk
greatest
ebvseroneg
recipi
ebvseroposit
allograft
ie
donor
seroposit
recipi
seroneg
r
situat
common
pediatr
transplant
recipi
adult
coinfect
cmv
higher
level
immunosuppress
monitor
consid
atrisk
individu
use
quantit
molecular
assay
eg
polymeras
chain
reaction
ebv
ebv
also
cofactor
lymphoid
malign
vzv
screen
use
identifi
seroneg
individu
histori
chickenpox
shingl
vaccin
transplant
hsv
screen
perform
center
despit
use
antivir
prophylaxi
posttranspl
period
vzv
serolog
statu
particularli
import
children
may
expos
school
antivir
vzv
immunoglobulin
prophylaxi
adult
atyp
present
infect
pneumonia
gastrointestin
diseas
herpesvirus
also
may
reactiv
serv
cofactor
cmv
fungal
infect
endem
region
kaposi
sarcomaassoci
herpesviru
caus
malign
hbv
surfac
antigen
hbsag
hbv
core
antibodi
hbcab
use
screen
purpos
see
chapter
detail
discuss
posit
hbv
surfac
antibodi
titer
indic
either
vaccin
prior
infect
hbcabigm
posit
suggest
activ
hbv
infect
wherea
igg
posit
suggest
remot
persist
infect
hbsagneg
hbcabiggposit
donor
may
viral
dna
liver
may
appropri
donor
hbvinfect
renal
recipi
quantit
assay
hbv
obtain
guid
therapi
presenc
hbsagneg
hbcabiggposit
assay
may
falseposit
result
reflect
true
latent
hbv
infect
hcv
infect
gener
progress
rapidli
immunosuppress
cmv
coinfect
see
chapter
detail
discuss
hcvseroposit
renal
transplant
candid
like
develop
cirrhosi
complic
liver
failur
therapi
hcv
infect
current
limit
particularli
transplant
popul
manag
often
conserv
involv
monitor
diseas
progress
quantit
molecular
viral
assay
intermitt
liver
biopsi
manag
like
chang
newer
hcv
antivir
agent
becom
avail
see
chapter
hivinfect
donor
rare
use
progress
recipi
infect
rapid
far
outweigh
benefit
transplant
base
current
criteria
donor
may
exclud
base
histor
evid
risk
factor
signific
hiv
infect
confirmatori
test
human
cell
lymphotrop
viru
htlvi
endem
caribbean
part
asia
japan
progress
htlviassoci
myelopathytrop
spastic
paraparesi
adult
cell
leukemialymphoma
htlvii
similar
htlvi
serolog
less
clearli
associ
diseas
use
organ
donor
gener
avoid
west
nile
viru
flaviviru
associ
viral
syndrom
meningoenceph
may
transmit
blood
transfus
organ
transplant
routin
screen
donor
advoc
area
endem
infect
donor
unexplain
chang
mental
statu
recent
viral
ill
neurolog
sign
avoid
sar
recent
describ
coronaviru
thought
associ
exposur
civet
anim
common
diet
certain
region
china
tissu
persist
prolong
infect
transplant
recipi
seem
sever
often
symptomat
organ
procur
exclud
patient
recent
acut
ill
meet
sar
criteria
pretranspl
period
use
obtain
travel
anim
environment
exposur
histori
updat
immun
counsel
recipi
regard
travel
food
infect
risk
ongo
infect
must
erad
transplant
two
form
infect
pose
special
riskbloodstream
infect
relat
vascular
access
includ
dialysi
pneumonia
put
patient
high
risk
subsequ
lung
infect
nosocomi
organ
sever
infect
commonli
encount
treat
clear
transplant
infect
ascit
periton
dialysi
fluid
also
must
clear
surgeri
urinari
tract
infect
must
elimin
antibiot
without
nephrectomi
similarli
skin
diseas
threaten
integr
one
primari
defens
infect
correct
even
requir
initi
immunosuppress
transplant
eg
initi
immunosuppress
treat
psoriasi
eczema
final
histori
one
episod
diverticul
initi
evalu
determin
whether
sigmoid
colectomi
done
transplant
among
import
consider
transplant
recipi
strongyloidiasi
tuberculosi
aid
strongyloid
hyperinfest
syndrom
hemorrhag
enterocol
pneumonia
gramneg
mix
bacteremia
mening
may
emerg
year
transplant
empir
pretransplant
therapi
strongyloidesseroposit
recipi
ivermectin
prevent
infect
incid
activ
tubercul
diseas
occurr
dissemin
infect
secondari
tuberculosi
higher
transplant
recipi
gener
popul
activ
tubercul
diseas
must
erad
transplant
major
antitubercul
drug
potenti
hepatotox
signific
drug
interact
common
antituberculosi
agent
immunosuppress
agent
patient
activ
infect
endem
region
highrisk
exposur
tuberculosi
therapi
initi
ppdposit
individu
transplant
judgment
may
use
optim
time
treatment
individu
without
evid
activ
pleuropulmonari
diseas
patient
greater
risk
tuberculosi
infect
exposur
includ
individu
prior
histori
activ
tuberculosi
signific
sign
old
tuberculosi
chest
radiograph
recent
tuberculin
reaction
convers
known
exposur
activ
diseas
proteincalori
malnutrit
cirrhosi
immunodefici
live
exposur
eg
shelter
group
hous
mani
patient
receiv
antiretrovir
therapi
hiv
infect
convert
progress
fatal
diseas
chronic
infect
control
complex
regimen
antivir
agent
highli
activ
antiretrovir
therapi
haart
haart
associ
reduc
viral
load
improv
lymphocyt
count
reduc
suscept
opportunist
infect
prehaart
era
organ
transplant
gener
associ
rapid
progress
aid
transplant
avoid
individu
prolong
diseasefre
surviv
haart
led
howev
reconsider
polici
renal
transplant
hiv
associ
good
outcom
individu
control
hiv
infect
absenc
hcv
coinfect
manag
requir
experi
immunosuppress
agent
variou
haart
regimen
spectrum
infect
immunocompromis
host
quit
broad
given
toxic
antimicrobi
agent
need
rapid
interrupt
infect
earli
specif
diagnosi
essenti
popul
advanc
diagnost
modal
eg
ct
magnet
reson
imag
molecular
microbiolog
techniqu
may
greatli
assist
process
need
invas
diagnost
tool
overemphas
howev
given
diminish
immun
respons
host
frequenc
multipl
simultan
process
invas
diagnosi
often
method
optim
care
initi
therapi
broad
necess
rapid
narrow
antimicrobi
spectrum
data
becom
avail
first
choic
therapi
reduc
intens
immunosuppress
understand
risk
approach
graft
reject
latent
viral
infect
tuberculosi
activ
seen
evid
excess
immunosuppress
contrast
intercurr
bacteri
fungal
infect
reduct
immunosuppress
might
reconsid
evid
resolut
infect
establish
select
specif
reduct
may
depend
organ
isol
similarli
revers
immun
deficit
eg
neutropenia
hypogammaglobulinemia
may
possibl
adjunct
therapi
eg
colonystimul
factor
antibodi
coinfect
viru
cmv
common
requir
addit
therapi
cytomegaloviru
cmv
import
pathogen
transplant
recipi
varieti
direct
indirect
effect
direct
effect
includ
follow
although
cmv
common
caus
clinic
infecti
diseas
syndrom
indirect
effect
viral
infect
equal
import
cmv
infect
produc
profound
suppress
varieti
host
defens
predispos
secondari
invas
pathogen
p
carinii
jiroveci
candida
aspergillu
bacteria
cmv
also
contribut
risk
graft
reject
ptld
infect
acceler
hcv
infect
mechan
effect
complex
includ
alter
cell
number
function
major
histocompat
complex
mhc
synthesi
elabor
array
proinflammatori
cytokin
chemokin
growth
factor
transmiss
cmv
transplant
recipi
occur
one
three
patternsprimari
infect
reactiv
superinfect
primari
cytomegaloviru
infect
primari
infect
occur
often
seroneg
individu
receiv
graft
latent
infect
seroposit
donor
r
subsequ
reactiv
viru
system
dissemin
transplant
forti
percent
patient
experi
direct
infecti
diseas
manifest
cmv
wherea
virem
often
without
symptom
primari
cmv
infect
also
may
occur
seroneg
individu
transfus
exposur
commun
diseas
may
sever
reactiv
cytomegaloviru
infect
reactiv
infect
seroposit
individu
reactiv
endogen
viru
transplant
r
convent
immunosuppress
therapi
use
eg
antilymphocyt
antibodi
treatment
approxim
experi
direct
infecti
diseas
syndrom
higher
rate
use
induct
antilymphocyt
therapi
fifti
percent
individu
virem
often
without
symptom
cytomegaloviru
superinfect
viru
may
reactiv
set
allograft
seroposit
donor
transplant
seroposit
recipi
r
control
cmv
infect
via
mhcrestrict
virusspecif
cytotox
lymphocyt
respons
cell
control
lymphocyt
seroconvers
marker
develop
host
immun
major
effector
activ
viru
natur
immunosuppress
therapi
administ
depletingantithymocyt
polyclon
monoclon
antibodi
direct
activ
viral
infect
mimick
alloimmun
respons
provok
elabor
tumor
necrosi
proinflammatori
cytokin
enhanc
viral
replic
cyclosporin
tacrolimu
rapamycin
prednison
puls
dose
limit
abil
reactiv
latent
cmv
wherea
azathioprin
mycophenol
mofetil
cyclophosphamid
moder
potent
term
promot
viral
reactiv
agent
also
perpetu
infect
establish
allograft
reject
major
stimulu
cmv
activ
vice
versa
cmv
infect
link
diminish
outcom
renal
allograft
reink
colleagu
show
patient
biopsi
specimen
reveal
evid
late
acut
reject
show
respons
antivir
therapi
multipl
studi
shown
prevent
cmv
infect
also
result
lower
incid
graft
reject
clinic
manag
cmv
includ
prevent
treatment
import
transplant
recipi
base
understand
caus
cmv
activ
avail
diagnost
techniqu
cmv
cultur
gener
slow
insensit
clinic
util
posit
cmv
cultur
shell
vial
cultur
deriv
respiratori
secret
urin
littl
diagnost
valuemani
patient
secret
cmv
absenc
invas
diseas
serolog
test
use
transplant
predict
risk
littl
valu
transplant
defin
clinic
diseas
statement
includ
measur
anticmv
igm
level
patient
seroconvert
cmv
evid
patient
expos
cmv
develop
degre
immun
seroconvers
transplant
gener
delay
howev
use
clinic
diagnosi
demonstr
cmv
inclus
tissu
set
compat
clinic
present
gold
standard
diagnosi
quantit
intens
cmv
infect
link
risk
infect
transplant
recipi
two
type
quantit
assay
developedmolecular
antigen
detect
assay
antigenemia
assay
semiquantit
fluoresc
assay
circul
neutrophil
stain
cmv
earli
antigen
taken
nonspecif
measur
total
viral
burden
bodi
molecular
assay
direct
dna
polymeras
chain
reaction
hybrid
captur
amplif
assay
highli
specif
sensit
detect
viremia
commonli
use
assay
includ
plasmabas
polymeras
chain
reaction
test
wholeblood
hybrid
captur
assay
wholeblood
plasmabas
assay
directli
compar
highest
viral
load
often
associ
tissueinvas
diseas
lowest
asymptomat
cmv
infect
viral
load
cmv
syndrom
vari
either
assay
use
manag
advent
quantit
assay
diagnosi
manag
cmv
infect
allow
noninvas
diagnosi
mani
patient
two
import
except
syndrom
cmv
assay
often
neg
invas
diagnosi
biopsi
may
need
central
role
assay
illustr
approach
manag
cmv
risk
see
tabl
schedul
screen
link
risk
infect
highrisk
patient
r
r
antilymphocyt
globulin
complet
prophylaxi
monthli
screen
perform
ensur
absenc
infect
month
patient
treat
cmv
infect
assay
provid
end
point
therapi
initi
prophylaxi
prevent
cmv
infect
must
individu
immunosuppress
regimen
patient
two
strategi
commonli
use
cmv
preventionunivers
prophylaxi
preemptiv
therapi
univers
prophylaxi
involv
give
antivir
therapi
atrisk
patient
begin
immedi
transplant
defin
period
preemptiv
therapi
quantit
assay
use
monitor
patient
predefin
interv
detect
earli
diseas
posit
assay
result
therapi
preemptiv
therapi
incur
extra
cost
monitor
coordin
outpati
care
reduc
cost
drug
inher
toxic
prophylaxi
possibl
advantag
prevent
cmv
infect
period
greatest
risk
also
diminish
infect
secondari
ebv
indirect
effect
cmv
ie
graft
reject
opportunist
infect
also
may
reduc
routin
prophylaxi
practic
neither
univers
prophylaxi
preemptiv
therapi
perfect
infrequ
breakthrough
diseas
ganciclovir
resist
observ
approach
given
risk
invas
infect
patient
risk
primari
infect
cmv
r
gener
given
prophylaxi
month
transplant
use
month
prophylaxi
patient
receiv
deplet
antit
lymphocyt
antibodi
group
candid
preemptiv
therapi
appropri
monitor
system
place
patient
complianc
good
current
data
support
use
univers
prophylaxi
preemptiv
therapi
howev
prevent
indirect
effect
cmv
infect
includ
ptld
opportunist
infect
allograft
reject
mortal
standard
care
treat
invas
cmv
diseas
least
week
intraven
ganciclovir
mgkg
twice
daili
dosag
adjust
renal
dysfunct
quantit
assay
cmv
neg
patient
slow
respond
therapi
seroneg
addit
month
cmv
hyperimmun
globulin
mgkgdose
intraven
given
everi
week
may
use
relaps
occur
primarili
patient
treat
beyond
achiev
neg
quantit
assay
use
complet
oral
regimen
treatment
appear
effect
except
invas
gastrointestin
diseas
treat
intraven
evid
good
respons
switch
oral
treatment
oral
treatment
close
monitor
quantit
viral
load
assay
follow
prophylaxi
month
oral
ganciclovir
valganciclovir
prophylaxi
base
creatinin
clearanc
approach
result
rare
symptomat
relaps
gener
prevent
emerg
antivir
resist
numer
issu
remain
note
role
oral
valganciclovir
treatment
remain
investig
agent
provid
good
bioavail
approv
indic
relaps
occur
gastrointestin
diseas
assay
use
follow
diseas
unreli
set
repeat
endoscopi
consid
ensur
clearanc
infect
optim
dose
valganciclovir
prophylaxi
renal
transplant
recipi
also
unclear
often
worth
measur
formal
creatinin
clearanc
ensur
adequ
dose
altern
therapi
avail
intraven
form
includ
foscarnet
cidofovir
foscarnet
use
extens
therapi
cmv
aid
patient
although
activ
ganciclovirresist
strain
cmv
prefer
combin
therapi
ganciclovir
foscarnet
organ
transplant
recipi
given
toxic
highdos
singleag
therapi
given
antivir
synergi
report
cidofovir
use
renal
transplant
recipi
often
nephrotox
foscarnet
cidofovir
may
exhibit
synergist
nephrotox
calcineurin
inhibitor
newer
class
agent
dihydroorot
dehydrogenas
inhibitor
leflunamid
approv
immunosuppress
treatment
rheumatolog
diseas
also
seem
use
activ
cmv
possibl
bk
polyomaviru
mirabavir
clinic
trial
cmv
prophylaxi
therapi
ebv
ubiquit
herpesviru
infect
b
lymphocyt
immunosuppress
transplant
recipi
primari
ebv
infect
relaps
absenc
antivir
immun
caus
mononucleosistyp
syndrom
gener
manifest
lymphocytosi
b
cell
without
lymphadenopathi
pharyng
mening
hepat
pancreat
also
observ
remittingrelaps
ebv
infect
common
children
may
reflect
interplay
evolv
antivir
immun
immunosuppress
regardless
mode
express
syndrom
suggest
rel
overimmunosuppress
ebv
also
play
central
role
pathogenesi
ptld
clearli
defin
risk
factor
ptld
primari
ebv
infect
increas
risk
ptld
ptld
may
occur
howev
absenc
ebv
infect
seroposit
patient
posttranspl
nonhodgkin
lymphoma
common
complic
solid
organ
transplant
lymphoma
constitut
tumor
among
adult
transplant
recipi
children
mortal
mani
death
associ
allograft
failur
withdraw
immunosuppress
treatment
malign
compar
gener
popul
ptld
increas
extranod
involv
poor
respons
convent
therapi
poor
outcom
spectrum
diseas
broad
rang
benign
polyclon
b
cell
infecti
mononucleosislik
diseas
malign
monoclon
lymphoma
diseas
b
cell
origin
although
cell
natur
killer
cell
null
cell
tumor
describ
ebvneg
ptld
describ
cell
ptld
shown
allograft
thought
reject
viral
infect
ptld
late
year
transplant
often
ebvneg
adult
see
chapter
clinic
present
ebvassoci
ptld
vari
includ
follow
unexplain
fever
fever
unknown
origin
mononucleosistyp
syndrom
fever
malais
without
pharyng
tonsil
often
diagnos
incident
tonsillectomi
specimen
often
lymphadenopathi
observ
serolog
test
use
diagnosi
acut
ebv
infect
ptld
transplant
quantit
ebv
viral
load
test
requir
diagnosi
manag
ptld
serial
assay
use
individu
patient
specif
viral
load
measur
assay
standard
directli
compar
center
data
suggest
assay
use
unfraction
whole
blood
prefer
plasma
sampl
ebv
viral
load
surveil
clinic
manag
depend
stage
diseas
polyclon
form
particularli
children
reestablish
immun
function
may
suffic
caus
ptld
regress
stage
possibl
antivir
therapi
might
util
given
viremia
role
ebv
immunosuppress
agent
progress
diseas
extranod
monoclon
malign
form
reduct
immunosuppress
may
use
altern
therapi
often
requir
renal
transplant
failur
regress
signific
reduct
immunosuppress
may
suggest
need
sacrific
allograft
patient
surviv
combin
antib
cell
therapi
rituximab
chemotherapi
chop
cyclophosphamid
hydroxydaunomycin
vincristin
oncovin
prednison
adopt
immunotherapi
stimul
cell
use
polyomavirus
identifi
transplant
recipi
associ
nephropathi
ureter
obstruct
bk
viru
associ
demyelin
diseas
brain
jc
viru
similar
aid
polyomavirus
small
nonenvelop
virus
coval
close
circular
doublestrand
dna
genom
adult
level
seropreval
seem
decrement
antibodi
posit
adulthood
bk
viru
seem
achiev
latenc
renal
tubular
epitheli
cell
jc
viru
also
isol
renal
tissu
seem
prefer
tropism
neural
tissu
reactiv
occur
immunodefici
immunosuppress
tissu
injuri
eg
ischemiareperfus
bk
viru
associ
rang
clinic
syndrom
immunocompromis
host
includ
viruria
viremia
ureter
ulcer
stenosi
hemorrhag
cystiti
activ
infect
renal
allograft
associ
progress
loss
graft
function
bk
nephropathi
approxim
renal
transplant
recipi
refer
polyomavirusassoci
nephropathi
pvan
bk
nephropathi
rare
recogn
recipi
extraren
organ
clinic
present
diseas
usual
steril
pyuria
reflect
shed
infect
tubular
ureter
epitheli
cell
cell
contain
sheet
viru
detect
urin
cytolog
decoy
cell
case
patient
present
diminish
renal
allograft
function
ureter
stenosi
obstruct
patient
etiolog
decreas
renal
function
must
care
evalu
eg
mechan
obstruct
drug
toxic
pyelonephr
reject
thrombosi
recurr
diseas
choic
must
made
increas
immunosuppress
treat
suspect
graft
reject
reduc
immunosuppress
allow
immun
system
control
infect
patient
bk
nephropathi
treat
increas
immunosuppress
high
incid
graft
loss
reduc
immunosuppress
may
stabil
renal
allograft
function
risk
graft
reject
polyomaassoci
nephropathi
manifest
characterist
histolog
featur
renal
dysfunct
found
renal
transplant
patient
risk
factor
nephropathi
poorli
defin
sever
risk
factor
implic
although
consensu
nickeleit
colleagu
found
cellular
reject
occur
commonli
patient
bk
nephropathi
control
studi
implic
highdos
immunosuppress
particularli
tacrolimu
mycophenol
mofetil
pulsedos
steroid
sever
ischemiareperfus
injuri
exposur
antilymphocyt
therapi
increas
number
hla
mismatch
donor
recipi
deceas
donor
renal
transplant
presenc
degre
viremia
pathogenesi
diseas
role
specif
immunosuppress
agent
confirm
greatest
incid
bk
nephropathi
center
intens
immunosuppress
regimen
diagnosi
use
urin
cytolog
detect
presenc
infect
decoy
cell
urin
approxim
sensit
bk
viru
infect
low
predict
valu
use
screen
tool
establish
firm
diagnosi
use
molecular
techniqu
screen
blood
urin
also
advoc
use
manag
establish
case
viral
clearanc
therapi
specif
diagnosi
hirsch
colleagu
show
patient
bk
nephropathi
plasma
viral
load
statist
significantli
higher
bk
viru
copi
per
ml
plasma
p
posit
predict
valu
neg
predict
valu
patient
without
diseas
given
presenc
viremia
renal
allograft
recipi
crucial
reduc
immunosuppress
whenev
possibl
possibl
coexist
reject
bk
infect
make
renal
biopsi
essenti
howev
manag
patient
renal
biopsi
specimen
initi
show
cytopath
chang
renal
epitheli
cell
gradual
evolut
cellular
infiltr
consist
diagnosi
interstiti
nephriti
fibrosi
often
promin
occasion
calcif
immunostain
crossreact
viru
show
patchi
stain
viral
particl
within
tubular
cell
treatment
accept
treatment
polyomavirusassoci
nephropathi
reduct
intens
immunosuppress
possibl
monitor
respons
maneuv
use
urin
cytolog
decoy
cell
viral
load
measur
blood
urin
unclear
whether
reduct
calcineurin
inhibitor
antimetabolit
consid
first
given
toxic
calcineurin
inhibitor
tubular
cell
role
injuri
activ
bk
viru
need
antibk
cell
activ
gener
reduc
agent
first
center
select
reduct
antimetabolit
first
regardless
approach
renal
function
drug
level
viral
load
must
monitor
care
center
advoc
use
cidofovir
bk
nephropathi
low
dose
mgkg
everi
week
signific
renal
toxic
may
observ
agent
may
add
littl
reduct
immunosuppress
alon
retransplant
achiev
patient
fail
allograftsposs
reflect
immun
develop
subsequ
discontinu
immunosuppress
infect
central
nervou
system
jc
polyomaviru
observ
uncommonli
renal
allograft
recipi
progress
multifoc
leukoencephalopathi
infect
gener
manifest
focal
neurolog
deficit
seizur
may
progress
death
extens
demyelin
progress
multifoc
leukoencephalopathi
may
confus
calcineurin
neurotox
may
respond
reduct
drug
level
believ
distinct
entiti
studi
way
addit
endem
mycos
transplant
recipi
risk
opportunist
infect
varieti
fungal
agent
import
candida
aspergillu
cryptococcu
neoforman
common
fungal
pathogen
transplant
patient
candida
nonalbican
strain
mucocutan
candid
infect
eg
oral
thrush
esophag
infect
cutan
infect
intertrigin
site
candid
vagin
common
diabet
highdos
steroid
therapi
broadspectrum
antibacteri
therapi
infect
usual
treatabl
correct
underli
metabol
abnorm
topic
therapi
clotrimazol
nystatin
thrush
also
may
complic
viral
hsv
cmv
toxic
drug
includ
mycophenol
mofetil
esophag
optim
manag
candid
infect
occur
associ
presenc
vascular
access
cathet
surgic
drain
bladder
cathet
requir
remov
foreign
bodi
system
antifung
therapi
fluconazol
echinocandin
special
problem
renal
transplant
recipi
candiduria
even
patient
asymptomat
particularli
individu
poor
bladder
function
obstruct
fungal
ball
develop
ureteropelv
junction
result
obstruct
uropathi
ascend
pyelonephr
possibl
system
dissemin
singl
posit
cultur
result
candida
speci
blood
specimen
necessit
system
antifung
therapi
find
carri
risk
viscer
invas
greater
popul
invas
aspergillosi
medic
emerg
transplant
recipi
portal
entri
lung
sinus
patient
skin
remain
two
speci
aspergillu
fumigatu
aspergillu
flavum
account
infect
although
amphotericinresist
isol
aspergillu
terreu
occasion
recogn
patholog
hallmark
invas
aspergillosi
blood
vessel
invas
account
three
clinic
characterist
infectiontissu
infarct
hemorrhag
system
dissemin
metastat
invas
earli
cours
transplant
central
nervou
system
involv
fungal
infect
often
due
aspergillu
year
later
transplant
fungi
zygomycet
dematiac
fungi
becom
promin
drug
choic
document
aspergillu
infect
voriconazol
despit
signific
interact
calcineurin
inhibitor
rapamycin
liposom
amphotericin
equal
effect
altern
combin
therapi
studi
surgic
usual
essenti
success
clearanc
invas
infect
central
nervou
system
infect
transplant
recipi
may
result
broad
spectrum
organ
infect
often
metastat
central
nervou
system
bloodstream
lung
viral
etiolog
includ
cmv
nodular
angiiti
hsv
meningoenceph
jc
viru
progress
multifoc
leukoencephalopathi
vzv
local
epidemiolog
west
nile
viru
eastern
equin
enceph
also
must
consid
common
bacteri
infect
addit
pneumococcu
includ
lyme
diseas
listeria
monocytogen
tuberculosi
nocardia
occasion
salmonella
brain
abscess
epidur
abscess
observ
may
particularli
problemat
secondari
methicillinresist
aureu
penicillinresist
pneumococcu
quinoloneresist
streptococci
note
earlier
fungi
may
metastat
lung
aspergillu
cryptococcu
also
may
spread
sinus
mucoracea
skin
dematiacea
bloodstream
histoplasma
pseudallescheriascedosporium
fusarium
given
spectrum
etiolog
precis
diagnosi
essenti
reason
empir
regimen
would
treat
pneumococcu
ceftriaxon
vancomycin
listeria
ampicillin
cryptococcu
fluconazol
amphotericin
herp
simplex
viru
acyclovir
await
data
lumbar
punctur
blood
cultur
radiograph
studi
noninfecti
etiolog
includ
calcineurin
inhibitor
toxic
lymphoma
metastat
cancer
includ
differenti
diagnosi
molecular
assay
hsv
biopsi
noninfecti
etiolog
may
need
diagnosi
cryptococc
infect
rare
seen
transplant
recipi
month
transplant
rel
intact
transplant
recipi
common
present
cryptococc
infect
asymptomat
pulmonari
nodul
often
activ
organ
present
chronic
neerdowel
patient
pneumonia
mening
common
skin
involv
site
tissu
injuri
cathet
prostat
bone
also
report
cryptococcosi
suspect
transplant
recipi
present
unexplain
headach
especi
accompani
fever
decreas
state
conscious
failur
thrive
unexplain
focal
skin
diseas
requir
biopsi
cultur
patholog
evalu
month
transplant
diagnosi
often
achiev
serum
cryptococc
antigen
detect
patient
lumbar
punctur
cell
count
cryptococc
antigen
studi
initi
treatment
probabl
best
liposom
amphotericin
flucytosin
obtain
serum
level
follow
highdos
fluconazol
cryptococc
antigen
clear
blood
cerebrospin
fluid
scar
hydrocephalu
may
observ
spectrum
potenti
pathogen
lung
transplant
recipi
broad
discuss
gener
concept
worth
mention
howev
infect
transplant
invas
diagnost
techniqu
often
necessari
host
depress
inflammatori
respons
immunocompromis
transplant
patient
may
greatli
modifi
delay
appear
pulmonari
lesion
radiograph
focal
multifoc
consolid
acut
onset
like
caus
bacteri
infect
similar
multifoc
lesion
subacut
chronic
progress
like
secondari
fungi
tuberculosi
nocardi
infect
larg
nodul
usual
sign
fungal
nocardi
infect
particularli
subacut
chronic
onset
subacut
diseas
diffus
abnorm
either
peribronchovascular
type
miliari
micronodul
usual
caus
virus
especi
cmv
pneumocysti
addit
clue
found
examin
pulmonari
lesion
cavit
suggest
necrot
infect
may
caus
fungi
aspergillu
mucoracea
nocardia
staphylococcu
certain
gramneg
bacilli
commonli
klebsiella
pneumonia
pseudomona
aeruginosa
ct
chest
use
chest
radiograph
neg
radiograph
find
subtl
nonspecif
ct
also
essenti
definit
extent
diseas
process
discern
possibl
simultan
process
superinfect
select
optim
invas
techniqu
achiev
patholog
diagnosi
risk
infect
pneumocysti
greatest
first
month
transplant
period
increas
immunosuppress
patient
receiv
trimethoprimsulfamethoxazol
altern
drug
prophylaxi
transplant
center
report
incid
pneumocysti
pneumonia
approxim
first
month
transplant
continu
risk
infect
three
overlap
group
transplant
recipi
recipi
requir
higher
normal
level
immunosuppress
prolong
period
poor
allograft
function
chronic
reject
recipi
chronic
cmv
infect
recipi
undergo
treatment
increas
level
immunodefici
cancer
chemotherapi
neutropenia
secondari
drug
toxic
expect
mortal
secondari
pneumocysti
pneumonia
increas
patient
cyclosporin
compar
immunocompromis
host
hallmark
infect
result
p
carinii
jiroveci
presenc
mark
hypoxemia
dyspnea
cough
pauciti
physic
radiolog
find
transplant
recipi
pneumocysti
pneumonia
gener
acut
subacut
develop
atyp
pneumocysti
infect
radiograph
clinic
may
seen
patient
coexist
pulmonari
infect
develop
diseas
receiv
prophylaxi
secondchoic
agent
eg
pentamidin
atovaquon
patient
outsid
usual
period
greatest
risk
p
carinii
jiroveci
pneumonia
may
present
indol
diseas
may
radiograph
confus
heart
failur
patient
diagnosi
often
made
invas
procedur
role
rapamycin
therapi
clinic
present
unknown
numer
patient
identifi
interstiti
pneumon
receiv
rapamycin
syndrom
may
occur
presenc
absenc
concomit
infect
adenoviru
respiratori
syncyti
viru
pneumocysti
characterist
hypoxemia
pneumocysti
pneumonia
produc
broad
alveolararteri
partial
pressur
oxygen
gradient
level
serum
lactat
dehydrogenas
elev
patient
pneumocysti
pneumonia
iuml
mani
diffus
pulmonari
process
also
increas
serum
lactat
dehydrogenas
level
howev
diagnost
pattern
exist
pneumocysti
pneumonia
routin
chest
radiograph
chest
radiograph
may
entir
normal
develop
classic
pattern
perihilar
interstiti
groundglass
infiltr
chest
ct
scan
sensit
diffus
interstiti
nodular
pattern
routin
radiograph
clinic
radiolog
manifest
p
carinii
jiroveci
pneumonia
virtual
ident
manifest
cmv
clinic
challeng
determin
whether
pathogen
present
signific
extrapulmonari
diseas
uncommon
transplant
recipi
bronchoalveolar
lavag
may
help
earli
therapi
trimethoprimsulfamethoxazol
prefer
renal
transplant
patient
toler
fulldos
trimethoprimsulfamethoxazol
prolong
period
reflect
elev
creatinin
owe
trimethoprim
compet
secret
kidney
toxic
sulfa
agent
renal
allograft
hydrat
gradual
initi
therapi
may
help
altern
therapi
less
desir
use
success
includ
intraven
pentamidin
atovaquon
clindamycin
primaquin
pyrimethamin
trimetrex
although
reduct
intens
immunosuppress
gener
consid
part
antiinfect
therapi
transplant
use
short
cours
adjunct
steroid
gradual
taper
gener
use
import
prevent
pneumocysti
infect
overemphas
lowdos
trimethoprim
sulfamethoxazol
well
toler
use
absenc
concret
data
show
true
allergi
interstiti
nephriti
altern
prophylact
strategi
includ
dapson
atovaquon
inhal
intraven
pentamidin
less
effect
trimethoprimsulfamethoxazol
use
patient
signific
allergi
sulfa
drug
trimethoprimsulfamethoxazol
effect
agent
prevent
infect
caus
pcarinii
jiroveci
advantag
trimethoprimsulfamethoxazol
includ
increas
efficaci
lower
cost
avail
oral
prepar
possibl
protect
organ
includ
gondii
isospora
belli
cyclospora
cayetanensi
nocardia
asteroid
common
urinari
respiratori
gastrointestin
bacteri
pathogen
altern
agent
lack
spectrum
activ
